Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc. (Nasdaq: SGHT) is an eyecare technology company that regularly issues news about its interventional glaucoma and dry eye businesses. As a manufacturer of ophthalmic medical devices, the company provides updates on its OMNI® and SION® glaucoma technologies and its TearCare® System for evaporative dry eye disease due to meibomian gland disease.
News for SGHT often includes quarterly and annual financial results, revenue guidance updates, and commentary on operating expenses and restructuring plans. The company uses press releases and Form 8-K filings to report results of operations, changes to loan agreements, and targeted cost-reduction initiatives designed to align its operating structure with long-term objectives.
Clinical and scientific developments are another recurring theme. Sight Sciences highlights peer-reviewed publications, systematic reviews, and meta-analyses evaluating the OMNI Surgical System in primary open-angle glaucoma, including standalone and cataract-combination procedures. It also reports on randomized controlled trials and guideline recognition related to the TearCare System in dry eye disease and meibomian gland disease.
Coverage decisions and reimbursement milestones frequently appear in the company’s announcements. Examples include jurisdiction-wide pricing for CPT® code 0563T, which describes the TearCare procedure, established by Medicare Administrative Contractors, and expanded coverage policies from commercial insurers for implant-free, minimally invasive glaucoma surgery procedures that include OMNI.
Corporate governance and leadership changes are also disclosed, such as executive promotions, board resignations, and new officer appointments. Investors following SGHT news can expect a mix of financial updates, clinical evidence summaries, reimbursement developments, and corporate actions related to its interventional eye care technologies.
Sight Sciences (Nasdaq: SGHT) announced that data from clinical studies of its OMNI® Surgical System will be presented at the 2022 American Glaucoma Society Annual Meeting in Nashville, TN, from March 3-6, 2022. Two posters are set for presentation, focusing on IOP fluctuation suppression and a retrospective analysis of 12-month outcomes in glaucoma treatments. The OMNI® system is a minimally invasive device aimed at reducing intraocular pressure in patients with primary open-angle glaucoma, enhancing treatment paradigms in eyecare.
Sight Sciences (Nasdaq: SGHT), an innovative eyecare technology company, announced its participation in the Citi Virtual Healthcare Conference scheduled for February 23, 2022, at 8:45 am PT. The management will engage in a fireside chat, accessible via a live and archived webcast on the company’s Investors section of its website. Sight Sciences focuses on transforming care standards through minimally invasive technologies, including the OMNI Surgical System for glaucoma and the TearCare System for dry eye treatment.
Sight Sciences (Nasdaq: SGHT) has launched the "Don't Wait for Too Late" educational campaign to promote minimally invasive glaucoma surgery (MIGS) as an early intervention for glaucoma. With glaucoma being a leading cause of irreversible blindness, early treatment is crucial. The use of MIGS, particularly the OMNI® Surgical System, offers new opportunities for patients with mild to moderate primary open-angle glaucoma (POAG), emphasizing reduced dependency on eye drops and better intraocular pressure management. The campaign aims to empower optometrists to recommend MIGS effectively.
Sight Sciences (Nasdaq: SGHT) announced preliminary financial results for Q4 and the full year 2021, forecasting total revenue between $14.5 million to $14.8 million for Q4, a 63% year-over-year increase, and full-year revenue between $48.8 million to $49.1 million, up 77%. Surgical Glaucoma revenues for Q4 are projected at $13.8 million to $14.0 million, while Dry Eye revenues are estimated at $0.7 million to $0.8 million. The company also highlighted significant accomplishments, including FDA clearances and advancements in clinical trials, with full results expected in March.
Sight Sciences (Nasdaq: SGHT) has received FDA 510(k) clearance for its TearCare® System to treat meibomian gland dysfunction (MGD), a leading cause of dry eye disease. This clearance allows for localized heat therapy combined with manual gland expression in adult patients with evaporative dry eye. The OLYMPIA study demonstrated significant improvements in tear film stability and symptoms post-treatment. Sight Sciences aims to expand insurance coverage for this treatment to increase patient access, addressing a significant unmet need in the eyecare community.
Sight Sciences (Nasdaq: SGHT) announced participation in the Piper Sandler Annual Virtual Healthcare Conference on November 22, 2021. The company focuses on innovative eyecare technology aimed at transforming care standards. Notable products include the OMNI® Surgical System, a minimally invasive glaucoma surgery device, and the TearCare® System, designed for treating evaporative dry eye disease. A recording of the fireside chat will be accessible on their investor website after the event.
Sight Sciences (Nasdaq: SGHT) announced significant data from the 12-month GEMINI clinical trial showing that the OMNI Surgical System effectively reduces intraocular pressure (IOP) and stabilizes daily IOP fluctuations in patients with open-angle glaucoma. The study included 149 patients, demonstrating that 95% achieved lower peak IOP post-surgery, with a 36% decrease in variability compared to preoperative levels. The results support the device’s potential to improve patient outcomes in glaucoma treatments, encouraging future regulatory developments.
Sight Sciences reported a record revenue of $13.1 million for Q3 2021, marking a 51% increase year-over-year. Gross margins improved to 84% from 70% in the previous year. Surgical glaucoma revenue rose by 58% to $12.4 million, while dry eye revenue declined by 15% to $0.7 million. The company expects total revenue for 2021 to be between $47.5 million and $48.5 million, reflecting an approximate 74% growth from 2020. However, net loss increased to $17.2 million in Q3, compared to $8.1 million a year earlier.
Sight Sciences (Nasdaq: SGHT) has announced FDA approval for its IDE trial aimed at assessing the safety and effectiveness of its new higher volume OMNI device for canal viscodilation in adults with primary open-angle glaucoma (POAG).
The PRECISION clinical trial, a three-armed randomized controlled trial, is set to evaluate the device's efficacy, potentially making it the largest of its kind for minimally invasive glaucoma surgery (MIGS). The study involves 459 patients and compares the higher volume OMNI to the iStent Inject.
Sight Sciences announced it will report its financial results for the quarter ending September 30, 2021, on November 10, 2021. The management will discuss the results in a conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the live and archived webcast through the company’s website or by dialing specified numbers with a passcode. Established in 2011, Sight Sciences focuses on developing products for eye diseases, including the OMNI® Surgical System and TearCare® System.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
